foxo3a Search Results


93
Addgene inc flag foxo3a tm
Flag Foxo3a Tm, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxo3a/FLAG-FOXO3a+TM+(Plasmid+%238361)/pm24284420-144-9-15
Average 93 stars, based on 1 article reviews
flag foxo3a tm - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc foxo3a
Fig. 5. Expression of miR-221 related genes in endothelial progenitor cells (EPCs) during endothelial–mesenchymal transition (EndMT). A. The expression of phosphatase and tensin homolog (PTEN), PI3KR1, <t>FoxO3a,</t> ESR1, and MMP-1 during EndMT was detected with reverse transcription polymerase chain reaction (RT-PCR). Normal – EPCs cultured in endothelial cell basal medium-2 (EBM-2) containing 20% fetal bovine serum (FBS); TGFβ1 – EPCs treated with TGF-β1, **p < 0.01; B. Western blot evaluating PTEN, p-FoxO3a, FoxO3a, and αSMA expression. Data expressed as maximum, minimum, median, percentiles 25 and percentiles 75, and analyzed with Kruskal–Wallis H test followed by Mann– Whitney U test for post hoc comparison. Normal – EPCs cultured in EBM-2 containing 20% FBS; TGFβ1 – EPCs treated with TGF-β1; TGFβ1 + miR221 mimics – miR-221 overexpressing EPCs treated with TGF-β1; TGFβ1 + miR221 mimics + PTEN cDNA – miR-221 and PTEN overexpressing EPCs treated with TGF-β1; normal + PTEN siRNA – PTEN silenced EPCs cultured in EBM-2 containing 20% FBS; *normal compared to normal + PTEN siRNA 5, p < 0.05; **normal compared to normal + PTEN siRNA, p < 0.01
Foxo3a, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxo3a/FoxO3a+Rabbit+mAb/pm34610220-58-73-77
Average 96 stars, based on 1 article reviews
foxo3a - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

95
Cell Signaling Technology Inc anti p foxo3a ser318 321
Fig. 5. Expression of miR-221 related genes in endothelial progenitor cells (EPCs) during endothelial–mesenchymal transition (EndMT). A. The expression of phosphatase and tensin homolog (PTEN), PI3KR1, <t>FoxO3a,</t> ESR1, and MMP-1 during EndMT was detected with reverse transcription polymerase chain reaction (RT-PCR). Normal – EPCs cultured in endothelial cell basal medium-2 (EBM-2) containing 20% fetal bovine serum (FBS); TGFβ1 – EPCs treated with TGF-β1, **p < 0.01; B. Western blot evaluating PTEN, p-FoxO3a, FoxO3a, and αSMA expression. Data expressed as maximum, minimum, median, percentiles 25 and percentiles 75, and analyzed with Kruskal–Wallis H test followed by Mann– Whitney U test for post hoc comparison. Normal – EPCs cultured in EBM-2 containing 20% FBS; TGFβ1 – EPCs treated with TGF-β1; TGFβ1 + miR221 mimics – miR-221 overexpressing EPCs treated with TGF-β1; TGFβ1 + miR221 mimics + PTEN cDNA – miR-221 and PTEN overexpressing EPCs treated with TGF-β1; normal + PTEN siRNA – PTEN silenced EPCs cultured in EBM-2 containing 20% FBS; *normal compared to normal + PTEN siRNA 5, p < 0.05; **normal compared to normal + PTEN siRNA, p < 0.01
Anti P Foxo3a Ser318 321, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxo3a/Phospho-FoxO3a+(Ser318%2F321)+Antibody/pmc06486184-157-15-31
Average 95 stars, based on 1 article reviews
anti p foxo3a ser318 321 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

94
Cell Signaling Technology Inc phospho mtor
Fig. 5. Expression of miR-221 related genes in endothelial progenitor cells (EPCs) during endothelial–mesenchymal transition (EndMT). A. The expression of phosphatase and tensin homolog (PTEN), PI3KR1, <t>FoxO3a,</t> ESR1, and MMP-1 during EndMT was detected with reverse transcription polymerase chain reaction (RT-PCR). Normal – EPCs cultured in endothelial cell basal medium-2 (EBM-2) containing 20% fetal bovine serum (FBS); TGFβ1 – EPCs treated with TGF-β1, **p < 0.01; B. Western blot evaluating PTEN, p-FoxO3a, FoxO3a, and αSMA expression. Data expressed as maximum, minimum, median, percentiles 25 and percentiles 75, and analyzed with Kruskal–Wallis H test followed by Mann– Whitney U test for post hoc comparison. Normal – EPCs cultured in EBM-2 containing 20% FBS; TGFβ1 – EPCs treated with TGF-β1; TGFβ1 + miR221 mimics – miR-221 overexpressing EPCs treated with TGF-β1; TGFβ1 + miR221 mimics + PTEN cDNA – miR-221 and PTEN overexpressing EPCs treated with TGF-β1; normal + PTEN siRNA – PTEN silenced EPCs cultured in EBM-2 containing 20% FBS; *normal compared to normal + PTEN siRNA 5, p < 0.05; **normal compared to normal + PTEN siRNA, p < 0.01
Phospho Mtor, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxo3a/Phospho-FoxO3a+(Ser294)+Antibody/pmc03259455-99-10-11
Average 94 stars, based on 1 article reviews
phospho mtor - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc rabbit antipfoxo3a ser253
Fig. 5. Expression of miR-221 related genes in endothelial progenitor cells (EPCs) during endothelial–mesenchymal transition (EndMT). A. The expression of phosphatase and tensin homolog (PTEN), PI3KR1, <t>FoxO3a,</t> ESR1, and MMP-1 during EndMT was detected with reverse transcription polymerase chain reaction (RT-PCR). Normal – EPCs cultured in endothelial cell basal medium-2 (EBM-2) containing 20% fetal bovine serum (FBS); TGFβ1 – EPCs treated with TGF-β1, **p < 0.01; B. Western blot evaluating PTEN, p-FoxO3a, FoxO3a, and αSMA expression. Data expressed as maximum, minimum, median, percentiles 25 and percentiles 75, and analyzed with Kruskal–Wallis H test followed by Mann– Whitney U test for post hoc comparison. Normal – EPCs cultured in EBM-2 containing 20% FBS; TGFβ1 – EPCs treated with TGF-β1; TGFβ1 + miR221 mimics – miR-221 overexpressing EPCs treated with TGF-β1; TGFβ1 + miR221 mimics + PTEN cDNA – miR-221 and PTEN overexpressing EPCs treated with TGF-β1; normal + PTEN siRNA – PTEN silenced EPCs cultured in EBM-2 containing 20% FBS; *normal compared to normal + PTEN siRNA 5, p < 0.05; **normal compared to normal + PTEN siRNA, p < 0.01
Rabbit Antipfoxo3a Ser253, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxo3a/Phospho-FoxO3a+(Ser253)+Antibody/pm38788601-131-45-49
Average 96 stars, based on 1 article reviews
rabbit antipfoxo3a ser253 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

90
Cell Signaling Technology Inc foxo3a sirnas
<t>FOXO3a</t> is downregulated and its promoter hypermethylated in breast cancer. a , b FOXO3a expression in the human breast epithelial cell line MCF-10A and a panel of breast cancer cell lines was measured by a qRT-PCR analysis and b western blot analysis. c Relative expression of FOXO3a in 20 pairs of breast cancer tissues (tumor) and corresponding adjacent normal breast tissues (normal). d Schematic representation of the CpG islands and bisulfite sequencing region in the FOXO3a promoter. Magenta words, CG sites for bisulfite sequencing; bold magenta words, the most significantly altered CG site in FOXO3a; Red region, input sequence; Blue region, CpG islands; Black curve, the trend of GC base percentage content; BSP F1 and R1, bisulfite forward primer and reverse primer. e Bisulfite sequencing analysis of the FOXO3a promoter region and the average methylation levels in normal ( n = 6) and breast cancer ( n = 6) tissues. f Methylation levels of the FOXO3a promoter region in MCF-10A cells and a panel of breast cancer cell lines. g MDA-MB-231 and BT549 cells were treated with 5-AzaC at indicated concentrations for 48 h, and FOXO3a expression was measured by western blot. h MDA-MB-231 and BT549 cells were transfected with DNMTs siRNA for 48 h, and FOXO3a mRNA expression was measured by qRT-PCR analysis. i Breast cancer cells were transfected with pCMV-DNMT1 for 48 h, and FOXO3a mRNA expression was measured by qRT-PCR analysis. A two-tailed Student’s t test was used for statistical analysis (* P < 0.05, ** P < 0.01, *** P < 0.001)
Foxo3a Sirnas, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxo3a/SignalSilence+FoxO3a+siRNA+II/pmc07206060-230-0-19
Average 90 stars, based on 1 article reviews
foxo3a sirnas - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
Cell Signaling Technology Inc anti foxo3a
<t>FOXO3a</t> is downregulated and its promoter hypermethylated in breast cancer. a , b FOXO3a expression in the human breast epithelial cell line MCF-10A and a panel of breast cancer cell lines was measured by a qRT-PCR analysis and b western blot analysis. c Relative expression of FOXO3a in 20 pairs of breast cancer tissues (tumor) and corresponding adjacent normal breast tissues (normal). d Schematic representation of the CpG islands and bisulfite sequencing region in the FOXO3a promoter. Magenta words, CG sites for bisulfite sequencing; bold magenta words, the most significantly altered CG site in FOXO3a; Red region, input sequence; Blue region, CpG islands; Black curve, the trend of GC base percentage content; BSP F1 and R1, bisulfite forward primer and reverse primer. e Bisulfite sequencing analysis of the FOXO3a promoter region and the average methylation levels in normal ( n = 6) and breast cancer ( n = 6) tissues. f Methylation levels of the FOXO3a promoter region in MCF-10A cells and a panel of breast cancer cell lines. g MDA-MB-231 and BT549 cells were treated with 5-AzaC at indicated concentrations for 48 h, and FOXO3a expression was measured by western blot. h MDA-MB-231 and BT549 cells were transfected with DNMTs siRNA for 48 h, and FOXO3a mRNA expression was measured by qRT-PCR analysis. i Breast cancer cells were transfected with pCMV-DNMT1 for 48 h, and FOXO3a mRNA expression was measured by qRT-PCR analysis. A two-tailed Student’s t test was used for statistical analysis (* P < 0.05, ** P < 0.01, *** P < 0.001)
Anti Foxo3a, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxo3a/FoxO3a+Rabbit+mAb/pmc12202021-36-4-11
Average 93 stars, based on 1 article reviews
anti foxo3a - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
Cell Signaling Technology Inc p foxo3
<t>FOXO3a</t> is downregulated and its promoter hypermethylated in breast cancer. a , b FOXO3a expression in the human breast epithelial cell line MCF-10A and a panel of breast cancer cell lines was measured by a qRT-PCR analysis and b western blot analysis. c Relative expression of FOXO3a in 20 pairs of breast cancer tissues (tumor) and corresponding adjacent normal breast tissues (normal). d Schematic representation of the CpG islands and bisulfite sequencing region in the FOXO3a promoter. Magenta words, CG sites for bisulfite sequencing; bold magenta words, the most significantly altered CG site in FOXO3a; Red region, input sequence; Blue region, CpG islands; Black curve, the trend of GC base percentage content; BSP F1 and R1, bisulfite forward primer and reverse primer. e Bisulfite sequencing analysis of the FOXO3a promoter region and the average methylation levels in normal ( n = 6) and breast cancer ( n = 6) tissues. f Methylation levels of the FOXO3a promoter region in MCF-10A cells and a panel of breast cancer cell lines. g MDA-MB-231 and BT549 cells were treated with 5-AzaC at indicated concentrations for 48 h, and FOXO3a expression was measured by western blot. h MDA-MB-231 and BT549 cells were transfected with DNMTs siRNA for 48 h, and FOXO3a mRNA expression was measured by qRT-PCR analysis. i Breast cancer cells were transfected with pCMV-DNMT1 for 48 h, and FOXO3a mRNA expression was measured by qRT-PCR analysis. A two-tailed Student’s t test was used for statistical analysis (* P < 0.05, ** P < 0.01, *** P < 0.001)
P Foxo3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxo3a/Phospho-FoxO3a+(Ser253)+Rabbit+mAb/pmc08292091-47-23-24
Average 94 stars, based on 1 article reviews
p foxo3 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Addgene inc ha foxo3a wt wild type
<t>FOXO3a</t> is downregulated and its promoter hypermethylated in breast cancer. a , b FOXO3a expression in the human breast epithelial cell line MCF-10A and a panel of breast cancer cell lines was measured by a qRT-PCR analysis and b western blot analysis. c Relative expression of FOXO3a in 20 pairs of breast cancer tissues (tumor) and corresponding adjacent normal breast tissues (normal). d Schematic representation of the CpG islands and bisulfite sequencing region in the FOXO3a promoter. Magenta words, CG sites for bisulfite sequencing; bold magenta words, the most significantly altered CG site in FOXO3a; Red region, input sequence; Blue region, CpG islands; Black curve, the trend of GC base percentage content; BSP F1 and R1, bisulfite forward primer and reverse primer. e Bisulfite sequencing analysis of the FOXO3a promoter region and the average methylation levels in normal ( n = 6) and breast cancer ( n = 6) tissues. f Methylation levels of the FOXO3a promoter region in MCF-10A cells and a panel of breast cancer cell lines. g MDA-MB-231 and BT549 cells were treated with 5-AzaC at indicated concentrations for 48 h, and FOXO3a expression was measured by western blot. h MDA-MB-231 and BT549 cells were transfected with DNMTs siRNA for 48 h, and FOXO3a mRNA expression was measured by qRT-PCR analysis. i Breast cancer cells were transfected with pCMV-DNMT1 for 48 h, and FOXO3a mRNA expression was measured by qRT-PCR analysis. A two-tailed Student’s t test was used for statistical analysis (* P < 0.05, ** P < 0.01, *** P < 0.001)
Ha Foxo3a Wt Wild Type, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxo3a/HA-FOXO3a+WT+(Plasmid+%231787)/pmc02848907-98-17-23
Average 94 stars, based on 1 article reviews
ha foxo3a wt wild type - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

85
Addgene inc pgex 4t3 gst foxo3 1 525aa tm 8351
<t>FOXO3a</t> is downregulated and its promoter hypermethylated in breast cancer. a , b FOXO3a expression in the human breast epithelial cell line MCF-10A and a panel of breast cancer cell lines was measured by a qRT-PCR analysis and b western blot analysis. c Relative expression of FOXO3a in 20 pairs of breast cancer tissues (tumor) and corresponding adjacent normal breast tissues (normal). d Schematic representation of the CpG islands and bisulfite sequencing region in the FOXO3a promoter. Magenta words, CG sites for bisulfite sequencing; bold magenta words, the most significantly altered CG site in FOXO3a; Red region, input sequence; Blue region, CpG islands; Black curve, the trend of GC base percentage content; BSP F1 and R1, bisulfite forward primer and reverse primer. e Bisulfite sequencing analysis of the FOXO3a promoter region and the average methylation levels in normal ( n = 6) and breast cancer ( n = 6) tissues. f Methylation levels of the FOXO3a promoter region in MCF-10A cells and a panel of breast cancer cell lines. g MDA-MB-231 and BT549 cells were treated with 5-AzaC at indicated concentrations for 48 h, and FOXO3a expression was measured by western blot. h MDA-MB-231 and BT549 cells were transfected with DNMTs siRNA for 48 h, and FOXO3a mRNA expression was measured by qRT-PCR analysis. i Breast cancer cells were transfected with pCMV-DNMT1 for 48 h, and FOXO3a mRNA expression was measured by qRT-PCR analysis. A two-tailed Student’s t test was used for statistical analysis (* P < 0.05, ** P < 0.01, *** P < 0.001)
Pgex 4t3 Gst Foxo3 1 525aa Tm 8351, supplied by Addgene inc, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxo3a/GST-FOXO3a+TM+1-506aa+(Plasmid+%238351)/pmc02423255-36-66-70
Average 85 stars, based on 1 article reviews
pgex 4t3 gst foxo3 1 525aa tm 8351 - by Bioz Stars, 2026-11
85/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc foxo3
Figure 1. Levels of the O-GlcNAcylated form of <t>FOXO3</t> are significantly increased in tumors of various digestive organs. A, O-GlcNAc levels in pooled lysates of pancreatic cancer tissues collected from patients were determined by Western blotting (n ¼ 12). B, Enlarged images of FOXO3 IHC of whole pancreatic tissue sections (n ¼ 16). Data were analyzed using an H-scoring assessment and are quantified and presented as the average from a 16-case experiment. C, FOXO3 and O-GlcNAc levels in tissues from pancreatic cancer patients were determined via FOXO3 IP and Western blotting (n ¼ 12). D, O-GlcNAc expression levels in tissues from individual pancreatic cancer patients were determined by Western blotting after FOXO3 IP (n ¼ 12). E, FOXO3 and O-GlcNAc levels in tissues from patients with various cancers were determined by Western blotting after FOXO3 IP from pooled lysates of pancreatic cancer (PC; n ¼ 12), hepatocellular carcinoma (HCC; n ¼ 10), gastric cancer (GC; n ¼ 10), colon cancer (CC; n ¼ 10), bile duct cancer (BD; n ¼ 5), and lung cancer (LC; n ¼ 10). All data were quantified and are presented as averages from three independent experiments (pooled samples). N, nontumor tissue; T, tumor tissue. Mean SD from three replicates of each sample. , P < 0.001; , P < 0.005; , P < 0.0001; N.S., not significant for indicated comparison. N.D., not determined.
Foxo3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxo3a/FoxO3a+Rabbit+mAb/10__1158_slash_0008___5472__can___17___3512-55-3-19
Average 96 stars, based on 1 article reviews
foxo3 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc akt
Figure 1. Levels of the O-GlcNAcylated form of <t>FOXO3</t> are significantly increased in tumors of various digestive organs. A, O-GlcNAc levels in pooled lysates of pancreatic cancer tissues collected from patients were determined by Western blotting (n ¼ 12). B, Enlarged images of FOXO3 IHC of whole pancreatic tissue sections (n ¼ 16). Data were analyzed using an H-scoring assessment and are quantified and presented as the average from a 16-case experiment. C, FOXO3 and O-GlcNAc levels in tissues from pancreatic cancer patients were determined via FOXO3 IP and Western blotting (n ¼ 12). D, O-GlcNAc expression levels in tissues from individual pancreatic cancer patients were determined by Western blotting after FOXO3 IP (n ¼ 12). E, FOXO3 and O-GlcNAc levels in tissues from patients with various cancers were determined by Western blotting after FOXO3 IP from pooled lysates of pancreatic cancer (PC; n ¼ 12), hepatocellular carcinoma (HCC; n ¼ 10), gastric cancer (GC; n ¼ 10), colon cancer (CC; n ¼ 10), bile duct cancer (BD; n ¼ 5), and lung cancer (LC; n ¼ 10). All data were quantified and are presented as averages from three independent experiments (pooled samples). N, nontumor tissue; T, tumor tissue. Mean SD from three replicates of each sample. , P < 0.001; , P < 0.005; , P < 0.0001; N.S., not significant for indicated comparison. N.D., not determined.
Akt, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/foxo3a/Phospho-FoxO1+(Thr24)%2FFoxO3a+(Thr32)+Antibody/10__4172_slash_2155___9554__1000399-65-23-24
Average 96 stars, based on 1 article reviews
akt - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

Image Search Results


Fig. 5. Expression of miR-221 related genes in endothelial progenitor cells (EPCs) during endothelial–mesenchymal transition (EndMT). A. The expression of phosphatase and tensin homolog (PTEN), PI3KR1, FoxO3a, ESR1, and MMP-1 during EndMT was detected with reverse transcription polymerase chain reaction (RT-PCR). Normal – EPCs cultured in endothelial cell basal medium-2 (EBM-2) containing 20% fetal bovine serum (FBS); TGFβ1 – EPCs treated with TGF-β1, **p < 0.01; B. Western blot evaluating PTEN, p-FoxO3a, FoxO3a, and αSMA expression. Data expressed as maximum, minimum, median, percentiles 25 and percentiles 75, and analyzed with Kruskal–Wallis H test followed by Mann– Whitney U test for post hoc comparison. Normal – EPCs cultured in EBM-2 containing 20% FBS; TGFβ1 – EPCs treated with TGF-β1; TGFβ1 + miR221 mimics – miR-221 overexpressing EPCs treated with TGF-β1; TGFβ1 + miR221 mimics + PTEN cDNA – miR-221 and PTEN overexpressing EPCs treated with TGF-β1; normal + PTEN siRNA – PTEN silenced EPCs cultured in EBM-2 containing 20% FBS; *normal compared to normal + PTEN siRNA 5, p < 0.05; **normal compared to normal + PTEN siRNA, p < 0.01

Journal: Advances in clinical and experimental medicine : official organ Wroclaw Medical University

Article Title: MicroRNA-221 inhibits the transition of endothelial progenitor cells to mesenchymal cells via the PTEN/FoxO3a signaling pathway.

doi: 10.17219/acem/141446

Figure Lengend Snippet: Fig. 5. Expression of miR-221 related genes in endothelial progenitor cells (EPCs) during endothelial–mesenchymal transition (EndMT). A. The expression of phosphatase and tensin homolog (PTEN), PI3KR1, FoxO3a, ESR1, and MMP-1 during EndMT was detected with reverse transcription polymerase chain reaction (RT-PCR). Normal – EPCs cultured in endothelial cell basal medium-2 (EBM-2) containing 20% fetal bovine serum (FBS); TGFβ1 – EPCs treated with TGF-β1, **p < 0.01; B. Western blot evaluating PTEN, p-FoxO3a, FoxO3a, and αSMA expression. Data expressed as maximum, minimum, median, percentiles 25 and percentiles 75, and analyzed with Kruskal–Wallis H test followed by Mann– Whitney U test for post hoc comparison. Normal – EPCs cultured in EBM-2 containing 20% FBS; TGFβ1 – EPCs treated with TGF-β1; TGFβ1 + miR221 mimics – miR-221 overexpressing EPCs treated with TGF-β1; TGFβ1 + miR221 mimics + PTEN cDNA – miR-221 and PTEN overexpressing EPCs treated with TGF-β1; normal + PTEN siRNA – PTEN silenced EPCs cultured in EBM-2 containing 20% FBS; *normal compared to normal + PTEN siRNA 5, p < 0.05; **normal compared to normal + PTEN siRNA, p < 0.01

Article Snippet: Total protein from the EPCs was extracted using radioimmunoprecipitation assay (RIPA) buffer and then separated using 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) before being transferred to polyvinylidene fluoride (PVDF) membranes using electrophoresis, and probed with primary antibodies against αSMA (Cat. No. CBL171; Merck Millipore, Billerica, USA), myocardin (Cat. No. 14760S; Cell Signaling Technology, Danvers, USA), PTEN (Cat. No. sc-7974; Santa Cruz Biotechnology, Dallas, USA), p-FoxO3a (Cat. No. sc-101683; Santa Cruz Biotechnology), FoxO3a (Cat. No. 2497s, Cell Signaling Technology), and β-actin (Cat. No. 3700; Cell Signaling Technology).

Techniques: Expressing, Reverse Transcription, Polymerase Chain Reaction, Reverse Transcription Polymerase Chain Reaction, Cell Culture, Western Blot, MANN-WHITNEY, Comparison

FOXO3a is downregulated and its promoter hypermethylated in breast cancer. a , b FOXO3a expression in the human breast epithelial cell line MCF-10A and a panel of breast cancer cell lines was measured by a qRT-PCR analysis and b western blot analysis. c Relative expression of FOXO3a in 20 pairs of breast cancer tissues (tumor) and corresponding adjacent normal breast tissues (normal). d Schematic representation of the CpG islands and bisulfite sequencing region in the FOXO3a promoter. Magenta words, CG sites for bisulfite sequencing; bold magenta words, the most significantly altered CG site in FOXO3a; Red region, input sequence; Blue region, CpG islands; Black curve, the trend of GC base percentage content; BSP F1 and R1, bisulfite forward primer and reverse primer. e Bisulfite sequencing analysis of the FOXO3a promoter region and the average methylation levels in normal ( n = 6) and breast cancer ( n = 6) tissues. f Methylation levels of the FOXO3a promoter region in MCF-10A cells and a panel of breast cancer cell lines. g MDA-MB-231 and BT549 cells were treated with 5-AzaC at indicated concentrations for 48 h, and FOXO3a expression was measured by western blot. h MDA-MB-231 and BT549 cells were transfected with DNMTs siRNA for 48 h, and FOXO3a mRNA expression was measured by qRT-PCR analysis. i Breast cancer cells were transfected with pCMV-DNMT1 for 48 h, and FOXO3a mRNA expression was measured by qRT-PCR analysis. A two-tailed Student’s t test was used for statistical analysis (* P < 0.05, ** P < 0.01, *** P < 0.001)

Journal: Cell Death and Differentiation

Article Title: Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis

doi: 10.1038/s41418-019-0389-3

Figure Lengend Snippet: FOXO3a is downregulated and its promoter hypermethylated in breast cancer. a , b FOXO3a expression in the human breast epithelial cell line MCF-10A and a panel of breast cancer cell lines was measured by a qRT-PCR analysis and b western blot analysis. c Relative expression of FOXO3a in 20 pairs of breast cancer tissues (tumor) and corresponding adjacent normal breast tissues (normal). d Schematic representation of the CpG islands and bisulfite sequencing region in the FOXO3a promoter. Magenta words, CG sites for bisulfite sequencing; bold magenta words, the most significantly altered CG site in FOXO3a; Red region, input sequence; Blue region, CpG islands; Black curve, the trend of GC base percentage content; BSP F1 and R1, bisulfite forward primer and reverse primer. e Bisulfite sequencing analysis of the FOXO3a promoter region and the average methylation levels in normal ( n = 6) and breast cancer ( n = 6) tissues. f Methylation levels of the FOXO3a promoter region in MCF-10A cells and a panel of breast cancer cell lines. g MDA-MB-231 and BT549 cells were treated with 5-AzaC at indicated concentrations for 48 h, and FOXO3a expression was measured by western blot. h MDA-MB-231 and BT549 cells were transfected with DNMTs siRNA for 48 h, and FOXO3a mRNA expression was measured by qRT-PCR analysis. i Breast cancer cells were transfected with pCMV-DNMT1 for 48 h, and FOXO3a mRNA expression was measured by qRT-PCR analysis. A two-tailed Student’s t test was used for statistical analysis (* P < 0.05, ** P < 0.01, *** P < 0.001)

Article Snippet: FOXO3a siRNAs (SignalSilence® FOXO3a siRNA I, Cat. No 6302; SignalSilence® FoxO3a siRNA II, Cat. No 6303) were purchased from Cell Signaling Technology (Denvers, MA, USA).

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Methylation Sequencing, Sequencing, Methylation, Transfection, Two Tailed Test

FOXO3a suppresses BCSC properties and tumorigenicity. a The top 10% of CD44 high or CD44 low subpopulations of MDA-MB-231 cells were isolated by flow cytometry sorting. b qRT-PCR analysis of FOXO3a expression in CD44 high or CD44 low subpopulations of MDA-MB-231 cells. c MDA-MB-231 and BT549 cells were transfected with FOXO3a-lentiviral vectors or pCMV-FOXO3a expression vector, and FOXO3a expression was measured by western blot. d MDA-MB-231 and BT549 cells were transfected with FOXO3a lentiviral vectors, and the percentages of CD44 high /CD44 low cells were measured by flow cytometry. e MDA-MB-231 and BT549 cells were transfected with pCMV-FOXO3a expression vector, and the percentages of ALDH + cells were measured by ALDEFLUOR assay. f Self-renewal of CSCs in control and FOXO3a-overexpressing cells as measured by a mammosphere formation assay. Scale bar, 50 μm. g Soft agar cloning in control and FOXO3a-overexpressing cells. Scale bar, 100 μm. g – i MCF-7 and T47D cells were transfected with FOXO3a siRNA, h FOXO3a expression was measured by qRT-PCR analysis; i the percentage of CD44 high /CD44 low cells were measured by flow cytometry; j the percentage of ALDH + cells was measured by ALDEFLUOR assay. A two-tailed Student’s t test was used for statistical analysis (* P < 0.05, ** P < 0.01, *** P < 0.001)

Journal: Cell Death and Differentiation

Article Title: Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis

doi: 10.1038/s41418-019-0389-3

Figure Lengend Snippet: FOXO3a suppresses BCSC properties and tumorigenicity. a The top 10% of CD44 high or CD44 low subpopulations of MDA-MB-231 cells were isolated by flow cytometry sorting. b qRT-PCR analysis of FOXO3a expression in CD44 high or CD44 low subpopulations of MDA-MB-231 cells. c MDA-MB-231 and BT549 cells were transfected with FOXO3a-lentiviral vectors or pCMV-FOXO3a expression vector, and FOXO3a expression was measured by western blot. d MDA-MB-231 and BT549 cells were transfected with FOXO3a lentiviral vectors, and the percentages of CD44 high /CD44 low cells were measured by flow cytometry. e MDA-MB-231 and BT549 cells were transfected with pCMV-FOXO3a expression vector, and the percentages of ALDH + cells were measured by ALDEFLUOR assay. f Self-renewal of CSCs in control and FOXO3a-overexpressing cells as measured by a mammosphere formation assay. Scale bar, 50 μm. g Soft agar cloning in control and FOXO3a-overexpressing cells. Scale bar, 100 μm. g – i MCF-7 and T47D cells were transfected with FOXO3a siRNA, h FOXO3a expression was measured by qRT-PCR analysis; i the percentage of CD44 high /CD44 low cells were measured by flow cytometry; j the percentage of ALDH + cells was measured by ALDEFLUOR assay. A two-tailed Student’s t test was used for statistical analysis (* P < 0.05, ** P < 0.01, *** P < 0.001)

Article Snippet: FOXO3a siRNAs (SignalSilence® FOXO3a siRNA I, Cat. No 6302; SignalSilence® FoxO3a siRNA II, Cat. No 6303) were purchased from Cell Signaling Technology (Denvers, MA, USA).

Techniques: Isolation, Flow Cytometry, Quantitative RT-PCR, Expressing, Transfection, Plasmid Preparation, Western Blot, Control, Tube Formation Assay, Cloning, Two Tailed Test

FOXO3a impairs tumorigenicity and tumor growth in vivo. a – d 5 × 10 6 , 5 × 10 5 , 5 × 10 4 , 5 × 10 3 , or 5 × 10 2 MDA-MB-231/control and MDA-MB-231/FOXO3a cells were implanted in nude mice ( n = 5 per group), a Representative images of the tumors are shown; b At the experimental endpoint, the tumors were dissected and imaged as indicated; c Tumor formation frequencies for different numbers of the indicated cells; d The tumor volume was measured on the indicated days. e , f 1 × 10 6 , 1 × 10 5 , 1 × 10 4 , or 1 × 10 3 T47D/control shRNA and T47D/FOXO3a shRNA cells were implanted in nude mice ( n = 4 per group), e At the experimental endpoint, the tumors were dissected and imaged as indicated; f Tumor formation frequencies for different numbers of the indicated cells. g The tumor volume was measured on the indicated days. h qRT-PCR detection of CD44 and ALDH1 expression in the indicated tumor tissues. A two-tailed Student’s t test was used for statistical analysis (* P < 0.05, ** P < 0.01)

Journal: Cell Death and Differentiation

Article Title: Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis

doi: 10.1038/s41418-019-0389-3

Figure Lengend Snippet: FOXO3a impairs tumorigenicity and tumor growth in vivo. a – d 5 × 10 6 , 5 × 10 5 , 5 × 10 4 , 5 × 10 3 , or 5 × 10 2 MDA-MB-231/control and MDA-MB-231/FOXO3a cells were implanted in nude mice ( n = 5 per group), a Representative images of the tumors are shown; b At the experimental endpoint, the tumors were dissected and imaged as indicated; c Tumor formation frequencies for different numbers of the indicated cells; d The tumor volume was measured on the indicated days. e , f 1 × 10 6 , 1 × 10 5 , 1 × 10 4 , or 1 × 10 3 T47D/control shRNA and T47D/FOXO3a shRNA cells were implanted in nude mice ( n = 4 per group), e At the experimental endpoint, the tumors were dissected and imaged as indicated; f Tumor formation frequencies for different numbers of the indicated cells. g The tumor volume was measured on the indicated days. h qRT-PCR detection of CD44 and ALDH1 expression in the indicated tumor tissues. A two-tailed Student’s t test was used for statistical analysis (* P < 0.05, ** P < 0.01)

Article Snippet: FOXO3a siRNAs (SignalSilence® FOXO3a siRNA I, Cat. No 6302; SignalSilence® FoxO3a siRNA II, Cat. No 6303) were purchased from Cell Signaling Technology (Denvers, MA, USA).

Techniques: In Vivo, Control, shRNA, Quantitative RT-PCR, Expressing, Two Tailed Test

FOXO3a suppresses BCSC properties via inhibition of FOXM1/SOX2 signaling. a MDA-MB-231 and BT549 cells were transfected with FOXO3a lentiviral vectors, and FOXO3a and FOXM1 expression was measured by western blot. b MCF-7 and T47D cells were transfected with FOXO3a shRNA, FOXO3a and FOXM1 expression was measured by western blot. c FOXO3a and FOXM1 expression in T47D tumor xenografts as analyzed by western blot. d – f MCF-7 and T47D cells were transfected with FOXO3a siRNA plus FOXM1 siRNA, d FOXO3a and FOXM1 expression was measured by Western blot; e The percentage of CD44 high /CD44 low cells was measured using flow cytometry; f The percentage of ALDH + cells was measured by ALDEFLUOR assay. g MCF-7 and T47D cells were transfected with FOXO3a shRNA, SOX2, and OCT4, and Nanog expression was measured by western blot. h MDA-MB-231 and BT549 cells were transfected with FOXO3a-expression vector (pCMV-FOXO3a), cells were fixed in 4% formaldehyde, and SOX2 was visualized with rabbit monoclonal antibody followed by the addition of secondary anti-rabbit antibody conjugated to PE (red). Nuclei were counterstained with DAPI (blue). Scale bar, 50 μm. i MCF-7 and T47D cells were transfected with FOXO3a siRNA plus FOXM1 siRNA, FOXO3a and FOXM1 expression was measured by western blot. j ChIP assay using chromatin prepared from MDA-MB-231 cells to analyze SOX2 promoter occupation by FOXO3a and FOXM1. The chromatin was precipitated with the anti-FOXO3a antibody or anti-FOXM1 antibody or control (IgG). The precipitated chromatin was then analyzed by qRT-PCR with primers specific for the putative FOX consensus binding sites or a control region. k MCF-7 cells were transfected with FOXO3a shRNA, or MDA-MB-231 cells were transfected with FOXO3a-lentiviral vectors, and the chromatin was precipitated with the anti-FOXM1 antibody or control (IgG). The precipitated chromatin was then analyzed by qRT-PCR and resolved in a 2% agarose gel. l T47D cells were transfected with FOXO3a shRNA or/and FOXM1 shRNA together with a luciferase reporter construct containing the wild-type or indicated mutant promoter regions. Relative luciferase activities were measured 48 h after transfection. Firefly luciferase activity of the reporter construct was normalized to internal Renilla luciferase activity. m T47D cells were transfected with FOXO3a siRNA plus SOX2 siRNA, the percentage of CD44 high /CD44 low cells was measured using flow cytometry. n MCF-7 and T47D cells were transfected with FOXO3a siRNA plus SOX2 siRNA, the percentage of ALDH + cells was measured by ALDEFLUOR assay. A two-tailed Student’s t test was used for statistical analysis (* P < 0.05, ** P < 0.01, *** P < 0.001)

Journal: Cell Death and Differentiation

Article Title: Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis

doi: 10.1038/s41418-019-0389-3

Figure Lengend Snippet: FOXO3a suppresses BCSC properties via inhibition of FOXM1/SOX2 signaling. a MDA-MB-231 and BT549 cells were transfected with FOXO3a lentiviral vectors, and FOXO3a and FOXM1 expression was measured by western blot. b MCF-7 and T47D cells were transfected with FOXO3a shRNA, FOXO3a and FOXM1 expression was measured by western blot. c FOXO3a and FOXM1 expression in T47D tumor xenografts as analyzed by western blot. d – f MCF-7 and T47D cells were transfected with FOXO3a siRNA plus FOXM1 siRNA, d FOXO3a and FOXM1 expression was measured by Western blot; e The percentage of CD44 high /CD44 low cells was measured using flow cytometry; f The percentage of ALDH + cells was measured by ALDEFLUOR assay. g MCF-7 and T47D cells were transfected with FOXO3a shRNA, SOX2, and OCT4, and Nanog expression was measured by western blot. h MDA-MB-231 and BT549 cells were transfected with FOXO3a-expression vector (pCMV-FOXO3a), cells were fixed in 4% formaldehyde, and SOX2 was visualized with rabbit monoclonal antibody followed by the addition of secondary anti-rabbit antibody conjugated to PE (red). Nuclei were counterstained with DAPI (blue). Scale bar, 50 μm. i MCF-7 and T47D cells were transfected with FOXO3a siRNA plus FOXM1 siRNA, FOXO3a and FOXM1 expression was measured by western blot. j ChIP assay using chromatin prepared from MDA-MB-231 cells to analyze SOX2 promoter occupation by FOXO3a and FOXM1. The chromatin was precipitated with the anti-FOXO3a antibody or anti-FOXM1 antibody or control (IgG). The precipitated chromatin was then analyzed by qRT-PCR with primers specific for the putative FOX consensus binding sites or a control region. k MCF-7 cells were transfected with FOXO3a shRNA, or MDA-MB-231 cells were transfected with FOXO3a-lentiviral vectors, and the chromatin was precipitated with the anti-FOXM1 antibody or control (IgG). The precipitated chromatin was then analyzed by qRT-PCR and resolved in a 2% agarose gel. l T47D cells were transfected with FOXO3a shRNA or/and FOXM1 shRNA together with a luciferase reporter construct containing the wild-type or indicated mutant promoter regions. Relative luciferase activities were measured 48 h after transfection. Firefly luciferase activity of the reporter construct was normalized to internal Renilla luciferase activity. m T47D cells were transfected with FOXO3a siRNA plus SOX2 siRNA, the percentage of CD44 high /CD44 low cells was measured using flow cytometry. n MCF-7 and T47D cells were transfected with FOXO3a siRNA plus SOX2 siRNA, the percentage of ALDH + cells was measured by ALDEFLUOR assay. A two-tailed Student’s t test was used for statistical analysis (* P < 0.05, ** P < 0.01, *** P < 0.001)

Article Snippet: FOXO3a siRNAs (SignalSilence® FOXO3a siRNA I, Cat. No 6302; SignalSilence® FoxO3a siRNA II, Cat. No 6303) were purchased from Cell Signaling Technology (Denvers, MA, USA).

Techniques: Inhibition, Transfection, Expressing, Western Blot, shRNA, Flow Cytometry, Plasmid Preparation, Control, Quantitative RT-PCR, Binding Assay, Agarose Gel Electrophoresis, Luciferase, Construct, Mutagenesis, Activity Assay, Two Tailed Test

SOX2 feedback inhibits FOXO3a expression by activating DNMT1. a MDA-MB-231 and BT549 cells were transfected with SOX2 siRNA, SOX2 and FOXO3a expressions were measured by western blot. b MCF-7 and T47D cells were transfected with SOX2 expression vector, SOX2 and FOXO3a expression was measured by western blot. c , d MCF-7 and T47D cells were transfected with SOX2 expression vector, DNMT1 expression was measured by qRT-PCR ( c ) and western blot ( d ). A two-tailed Student’s t test was used for statistical analysis. (** P < 0.01). e MCF-7 and T47D cells were transfected with SOX2 expression vector plus DNMT1 siRNA, the expressions of DNMT1, SOX2, and FOXO3a were measured by western blot. f Illustration of SOX2 feedback inhibits FOXO3a expression by activating DNMT1

Journal: Cell Death and Differentiation

Article Title: Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis

doi: 10.1038/s41418-019-0389-3

Figure Lengend Snippet: SOX2 feedback inhibits FOXO3a expression by activating DNMT1. a MDA-MB-231 and BT549 cells were transfected with SOX2 siRNA, SOX2 and FOXO3a expressions were measured by western blot. b MCF-7 and T47D cells were transfected with SOX2 expression vector, SOX2 and FOXO3a expression was measured by western blot. c , d MCF-7 and T47D cells were transfected with SOX2 expression vector, DNMT1 expression was measured by qRT-PCR ( c ) and western blot ( d ). A two-tailed Student’s t test was used for statistical analysis. (** P < 0.01). e MCF-7 and T47D cells were transfected with SOX2 expression vector plus DNMT1 siRNA, the expressions of DNMT1, SOX2, and FOXO3a were measured by western blot. f Illustration of SOX2 feedback inhibits FOXO3a expression by activating DNMT1

Article Snippet: FOXO3a siRNAs (SignalSilence® FOXO3a siRNA I, Cat. No 6302; SignalSilence® FoxO3a siRNA II, Cat. No 6303) were purchased from Cell Signaling Technology (Denvers, MA, USA).

Techniques: Expressing, Transfection, Western Blot, Plasmid Preparation, Quantitative RT-PCR, Two Tailed Test

Dysregulation of DNMT1/FOXO3a/FOXM1/SOX2 signaling exhibits clinical significance. a Relative expression of FOXM1, SOX2, and DNMT1 in 20 pairs of breast cancer tissues (tumor) and their corresponding adjacent normal breast tissues (normal). b Representative immunohistochemical staining of FOXO3a, FOXM1, SOX2, and DNMT1 protein expression in breast cancer tissue specimens. c FOXO3a, FOXM1, SOX2, and DNMT1 expression scores in breast cancer tissue specimens. The breast cancer tissue sections were quantitatively scored according to the percentage of positive cells and staining intensity as described in the “Materials and Methods.” d Representative examples of the FOXO3a, FOXM1, SOX2, and DNMT1 staining in the same breast cancer tissue set. (left) FOXO3a low /FOXM1 high /SOX2 high /Dnmt1 high ; (right) FOXO3a high / FOXM1 low /SOX2 low /Dnmt1 low . e Clinical correlations among the network of regulatory genes, FOXO3a, FOXM1, SOX2, and DNMT1 in breast cancer samples. f Survival curves of breast cancer patients with low expression versus high expression of FOXO3a, FOXM1, SOX2, and DNMT1

Journal: Cell Death and Differentiation

Article Title: Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis

doi: 10.1038/s41418-019-0389-3

Figure Lengend Snippet: Dysregulation of DNMT1/FOXO3a/FOXM1/SOX2 signaling exhibits clinical significance. a Relative expression of FOXM1, SOX2, and DNMT1 in 20 pairs of breast cancer tissues (tumor) and their corresponding adjacent normal breast tissues (normal). b Representative immunohistochemical staining of FOXO3a, FOXM1, SOX2, and DNMT1 protein expression in breast cancer tissue specimens. c FOXO3a, FOXM1, SOX2, and DNMT1 expression scores in breast cancer tissue specimens. The breast cancer tissue sections were quantitatively scored according to the percentage of positive cells and staining intensity as described in the “Materials and Methods.” d Representative examples of the FOXO3a, FOXM1, SOX2, and DNMT1 staining in the same breast cancer tissue set. (left) FOXO3a low /FOXM1 high /SOX2 high /Dnmt1 high ; (right) FOXO3a high / FOXM1 low /SOX2 low /Dnmt1 low . e Clinical correlations among the network of regulatory genes, FOXO3a, FOXM1, SOX2, and DNMT1 in breast cancer samples. f Survival curves of breast cancer patients with low expression versus high expression of FOXO3a, FOXM1, SOX2, and DNMT1

Article Snippet: FOXO3a siRNAs (SignalSilence® FOXO3a siRNA I, Cat. No 6302; SignalSilence® FoxO3a siRNA II, Cat. No 6303) were purchased from Cell Signaling Technology (Denvers, MA, USA).

Techniques: Expressing, Immunohistochemical staining, Staining

Inhibition of DNMT activity suppresses tumorigenesis and tumor growth via regulation of FOXO3a/FOXM1/SOX2 signaling. a MDA-MB-231 and BT549 cells were treated with 5-AzaC at indicated concentrations for 48 h, FOXM1 and SOX2 expression was measured by western blot. b , c MDA-MB-231 and BT549 cells were transfected with FOXO3a shRNA, then treated with 5-AzaC, b the expression of FOXO3a, FOXM1, and SOX2 was measured by western blot; c Mammosphere formation was measured. d – g MDA-MB-231 cells tranfected with FOXO3a shRNA or control shRNA were implanted in nude mice and palpable tumors were allowed to develop for 7 days. 5-AzaC at a dose of 0.5 mg/kg body weight was injected every other day for 4 weeks, d Representative images of the tumors are shown; e At the end of treatment, tumors were excised and subjected to further analyses; f Tumor sizes were measured at indicated time intervals; g Tumor weights were measured. h Tumor tissues derived from mice were resected, fixed, sectioned, and placed on slides. Tumor specimens were subjected to immunohistochemical staining with antibodies specific to FOXO3a, FOXM1, and SOX2. A two-tailed Student’s t test was used for statistical analysis. (** P < 0.01, *** P < 0.01)

Journal: Cell Death and Differentiation

Article Title: Downregulation of FOXO3a by DNMT1 promotes breast cancer stem cell properties and tumorigenesis

doi: 10.1038/s41418-019-0389-3

Figure Lengend Snippet: Inhibition of DNMT activity suppresses tumorigenesis and tumor growth via regulation of FOXO3a/FOXM1/SOX2 signaling. a MDA-MB-231 and BT549 cells were treated with 5-AzaC at indicated concentrations for 48 h, FOXM1 and SOX2 expression was measured by western blot. b , c MDA-MB-231 and BT549 cells were transfected with FOXO3a shRNA, then treated with 5-AzaC, b the expression of FOXO3a, FOXM1, and SOX2 was measured by western blot; c Mammosphere formation was measured. d – g MDA-MB-231 cells tranfected with FOXO3a shRNA or control shRNA were implanted in nude mice and palpable tumors were allowed to develop for 7 days. 5-AzaC at a dose of 0.5 mg/kg body weight was injected every other day for 4 weeks, d Representative images of the tumors are shown; e At the end of treatment, tumors were excised and subjected to further analyses; f Tumor sizes were measured at indicated time intervals; g Tumor weights were measured. h Tumor tissues derived from mice were resected, fixed, sectioned, and placed on slides. Tumor specimens were subjected to immunohistochemical staining with antibodies specific to FOXO3a, FOXM1, and SOX2. A two-tailed Student’s t test was used for statistical analysis. (** P < 0.01, *** P < 0.01)

Article Snippet: FOXO3a siRNAs (SignalSilence® FOXO3a siRNA I, Cat. No 6302; SignalSilence® FoxO3a siRNA II, Cat. No 6303) were purchased from Cell Signaling Technology (Denvers, MA, USA).

Techniques: Inhibition, Activity Assay, Expressing, Western Blot, Transfection, shRNA, Control, Injection, Derivative Assay, Immunohistochemical staining, Staining, Two Tailed Test

Figure 1. Levels of the O-GlcNAcylated form of FOXO3 are significantly increased in tumors of various digestive organs. A, O-GlcNAc levels in pooled lysates of pancreatic cancer tissues collected from patients were determined by Western blotting (n ¼ 12). B, Enlarged images of FOXO3 IHC of whole pancreatic tissue sections (n ¼ 16). Data were analyzed using an H-scoring assessment and are quantified and presented as the average from a 16-case experiment. C, FOXO3 and O-GlcNAc levels in tissues from pancreatic cancer patients were determined via FOXO3 IP and Western blotting (n ¼ 12). D, O-GlcNAc expression levels in tissues from individual pancreatic cancer patients were determined by Western blotting after FOXO3 IP (n ¼ 12). E, FOXO3 and O-GlcNAc levels in tissues from patients with various cancers were determined by Western blotting after FOXO3 IP from pooled lysates of pancreatic cancer (PC; n ¼ 12), hepatocellular carcinoma (HCC; n ¼ 10), gastric cancer (GC; n ¼ 10), colon cancer (CC; n ¼ 10), bile duct cancer (BD; n ¼ 5), and lung cancer (LC; n ¼ 10). All data were quantified and are presented as averages from three independent experiments (pooled samples). N, nontumor tissue; T, tumor tissue. Mean SD from three replicates of each sample. , P < 0.001; , P < 0.005; , P < 0.0001; N.S., not significant for indicated comparison. N.D., not determined.

Journal: Cancer Research

Article Title: O-GlcNAcylation of the Tumor Suppressor FOXO3 Triggers Aberrant Cancer Cell Growth

doi: 10.1158/0008-5472.can-17-3512

Figure Lengend Snippet: Figure 1. Levels of the O-GlcNAcylated form of FOXO3 are significantly increased in tumors of various digestive organs. A, O-GlcNAc levels in pooled lysates of pancreatic cancer tissues collected from patients were determined by Western blotting (n ¼ 12). B, Enlarged images of FOXO3 IHC of whole pancreatic tissue sections (n ¼ 16). Data were analyzed using an H-scoring assessment and are quantified and presented as the average from a 16-case experiment. C, FOXO3 and O-GlcNAc levels in tissues from pancreatic cancer patients were determined via FOXO3 IP and Western blotting (n ¼ 12). D, O-GlcNAc expression levels in tissues from individual pancreatic cancer patients were determined by Western blotting after FOXO3 IP (n ¼ 12). E, FOXO3 and O-GlcNAc levels in tissues from patients with various cancers were determined by Western blotting after FOXO3 IP from pooled lysates of pancreatic cancer (PC; n ¼ 12), hepatocellular carcinoma (HCC; n ¼ 10), gastric cancer (GC; n ¼ 10), colon cancer (CC; n ¼ 10), bile duct cancer (BD; n ¼ 5), and lung cancer (LC; n ¼ 10). All data were quantified and are presented as averages from three independent experiments (pooled samples). N, nontumor tissue; T, tumor tissue. Mean SD from three replicates of each sample. , P < 0.001; , P < 0.005; , P < 0.0001; N.S., not significant for indicated comparison. N.D., not determined.

Article Snippet: Antibodies specific for FOXO3 (2497, 12829), p21 (2947), CDK2 (2546), CDK-4 (12790), and cyclin D1 (2978) were purchased from Cell Signaling Technology.

Techniques: Western Blot, Expressing, Comparison

Figure 2. Schematic workflow of FOXO3 protein separation, proteomic analysis, and O-GlcNAc-modified site identification. A, Purification of FOXO3 from FOX-OV cells via pH- fractionation and IP, and the identification of O-GlcNAc sites in FOXO3 by MS. B, FOXO3 expression levels in transfected cells were determined by Western blot analysis. C, FOXO3 expression levels in Agilent 3100 OFFGEL fractionator-enriched samples were determined by Western blotting. D, Schematic diagram of seven identified novel O-GlcNAc-modified sites within FOXO3, determined from FOX-OV cells via MS. All presented data were quantified from three independent experiments. N, N-terminus; Forkhead, forkhead domain; L, nuclear localization sequences; E, nuclear export sequences; TAD, transactivation domain; C, C-terminus.

Journal: Cancer Research

Article Title: O-GlcNAcylation of the Tumor Suppressor FOXO3 Triggers Aberrant Cancer Cell Growth

doi: 10.1158/0008-5472.can-17-3512

Figure Lengend Snippet: Figure 2. Schematic workflow of FOXO3 protein separation, proteomic analysis, and O-GlcNAc-modified site identification. A, Purification of FOXO3 from FOX-OV cells via pH- fractionation and IP, and the identification of O-GlcNAc sites in FOXO3 by MS. B, FOXO3 expression levels in transfected cells were determined by Western blot analysis. C, FOXO3 expression levels in Agilent 3100 OFFGEL fractionator-enriched samples were determined by Western blotting. D, Schematic diagram of seven identified novel O-GlcNAc-modified sites within FOXO3, determined from FOX-OV cells via MS. All presented data were quantified from three independent experiments. N, N-terminus; Forkhead, forkhead domain; L, nuclear localization sequences; E, nuclear export sequences; TAD, transactivation domain; C, C-terminus.

Article Snippet: Antibodies specific for FOXO3 (2497, 12829), p21 (2947), CDK2 (2546), CDK-4 (12790), and cyclin D1 (2978) were purchased from Cell Signaling Technology.

Techniques: Fractionation, Expressing, Transfection, Western Blot

Figure 3. qRT-PCR analysis of target gene expression in response to FOXO3 and various posttranslational modification mutants within FOXO3. A, FOXO3 target gene expression (FasL, MnSod, Nib, p27, and p21) was measured by qRT-PCR. B, Changes in p21 expression in FOX-OV and S284-mutated cell lines were measured using qRT-PCR. C, Changes in p21 expression in FOX-OV and S284-mutated cell lines were analyzed by Western blotting. All data were quantified and are presented as the means standard deviations from three independent experiments. Mean SD from three replicates of each sample. , P < 0.005; N.S., not significant for indicated comparison.

Journal: Cancer Research

Article Title: O-GlcNAcylation of the Tumor Suppressor FOXO3 Triggers Aberrant Cancer Cell Growth

doi: 10.1158/0008-5472.can-17-3512

Figure Lengend Snippet: Figure 3. qRT-PCR analysis of target gene expression in response to FOXO3 and various posttranslational modification mutants within FOXO3. A, FOXO3 target gene expression (FasL, MnSod, Nib, p27, and p21) was measured by qRT-PCR. B, Changes in p21 expression in FOX-OV and S284-mutated cell lines were measured using qRT-PCR. C, Changes in p21 expression in FOX-OV and S284-mutated cell lines were analyzed by Western blotting. All data were quantified and are presented as the means standard deviations from three independent experiments. Mean SD from three replicates of each sample. , P < 0.005; N.S., not significant for indicated comparison.

Article Snippet: Antibodies specific for FOXO3 (2497, 12829), p21 (2947), CDK2 (2546), CDK-4 (12790), and cyclin D1 (2978) were purchased from Cell Signaling Technology.

Techniques: Quantitative RT-PCR, Targeted Gene Expression, Expressing, Western Blot, Comparison

Figure 4. Effect of a posttranslational modification in FOXO3 (S284) on the maintenance of oncogenic properties in PANC-1 cells. A, The total cell counts of various FOXO3 mutant pancreatic cancer cell lines. B, The cell proliferation ratios of various FOXO3 mutants were measured using a WST-1 assay. C, The distributions of various FOXO3 mutants were measured using crystal violet staining. D, Various FOXO3 mutants were subjected to a FACS cell-cycle analysis. All data were quantified and are presented as the means standard deviations from three independent experiments. Mean SD from three replicates of each sample. , P < 0.001; , P < 0.005; , P < 0.0001; N.S., not significant for indicated comparison.

Journal: Cancer Research

Article Title: O-GlcNAcylation of the Tumor Suppressor FOXO3 Triggers Aberrant Cancer Cell Growth

doi: 10.1158/0008-5472.can-17-3512

Figure Lengend Snippet: Figure 4. Effect of a posttranslational modification in FOXO3 (S284) on the maintenance of oncogenic properties in PANC-1 cells. A, The total cell counts of various FOXO3 mutant pancreatic cancer cell lines. B, The cell proliferation ratios of various FOXO3 mutants were measured using a WST-1 assay. C, The distributions of various FOXO3 mutants were measured using crystal violet staining. D, Various FOXO3 mutants were subjected to a FACS cell-cycle analysis. All data were quantified and are presented as the means standard deviations from three independent experiments. Mean SD from three replicates of each sample. , P < 0.001; , P < 0.005; , P < 0.0001; N.S., not significant for indicated comparison.

Article Snippet: Antibodies specific for FOXO3 (2497, 12829), p21 (2947), CDK2 (2546), CDK-4 (12790), and cyclin D1 (2978) were purchased from Cell Signaling Technology.

Techniques: Mutagenesis, WST-1 Assay, Staining, Cell Cycle Assay, Comparison

Figure 5. Label-free LC–MS quantification analysis of FOX-OV and FOX-S284A cells. A, Differentially expressed proteins between FOX-OV and FOX-S284A cells were determined using a heat map analysis. B, Differentially expressed proteins between FOX-OV cells and FOX-S284A cells were determined using a volcano plot. C, Top, summary of cancer signaling pathway influenced by O-GlcNAcylation at FOXO3 S284. Bottom, differentially expressed proteins between FOX-OV cells and FOX-S284A cells were determined using label-free LC–MS and a protein–protein interaction map. D, Pattern of differential protein expression in S284A cells. A GO annotation of differentially expressed proteins from various S284 mutants based on the results of a label-free LC–MS analysis was performed using the PANTHER.

Journal: Cancer Research

Article Title: O-GlcNAcylation of the Tumor Suppressor FOXO3 Triggers Aberrant Cancer Cell Growth

doi: 10.1158/0008-5472.can-17-3512

Figure Lengend Snippet: Figure 5. Label-free LC–MS quantification analysis of FOX-OV and FOX-S284A cells. A, Differentially expressed proteins between FOX-OV and FOX-S284A cells were determined using a heat map analysis. B, Differentially expressed proteins between FOX-OV cells and FOX-S284A cells were determined using a volcano plot. C, Top, summary of cancer signaling pathway influenced by O-GlcNAcylation at FOXO3 S284. Bottom, differentially expressed proteins between FOX-OV cells and FOX-S284A cells were determined using label-free LC–MS and a protein–protein interaction map. D, Pattern of differential protein expression in S284A cells. A GO annotation of differentially expressed proteins from various S284 mutants based on the results of a label-free LC–MS analysis was performed using the PANTHER.

Article Snippet: Antibodies specific for FOXO3 (2497, 12829), p21 (2947), CDK2 (2546), CDK-4 (12790), and cyclin D1 (2978) were purchased from Cell Signaling Technology.

Techniques: Liquid Chromatography with Mass Spectroscopy, Expressing

Figure 6. Cell-cycle regulatory proteins were controlled by O-GlcNAc at FOXO3 S284 through MDM2. A, The mRNA expression levels of MDM2-p53 pathway–related proteins (MDM2, p53, and p21) in various FOXO3 mutants were determined by qRT-PCR. B, The expression levels of cell-cycle regulatory proteins (FOXO3, p53, p21, MDM2, CDK2, CDK4, cyclin D1, cyclin E, and GAPDH) in various FOXO3 mutants were determined by Western blotting (see details in Supplementary Fig. S4). This figure was drawn from the information present in the top panel of Fig. 5C. C, This figure illustrates how O-GlcNAc at FOXO3 S284 could activate MDM2 by which p21 is suppressed based on the schematic summary of the LC–MS analysis. , P < 0.005; , P < 0.0001; N.S., not significant for indicated comparison.

Journal: Cancer Research

Article Title: O-GlcNAcylation of the Tumor Suppressor FOXO3 Triggers Aberrant Cancer Cell Growth

doi: 10.1158/0008-5472.can-17-3512

Figure Lengend Snippet: Figure 6. Cell-cycle regulatory proteins were controlled by O-GlcNAc at FOXO3 S284 through MDM2. A, The mRNA expression levels of MDM2-p53 pathway–related proteins (MDM2, p53, and p21) in various FOXO3 mutants were determined by qRT-PCR. B, The expression levels of cell-cycle regulatory proteins (FOXO3, p53, p21, MDM2, CDK2, CDK4, cyclin D1, cyclin E, and GAPDH) in various FOXO3 mutants were determined by Western blotting (see details in Supplementary Fig. S4). This figure was drawn from the information present in the top panel of Fig. 5C. C, This figure illustrates how O-GlcNAc at FOXO3 S284 could activate MDM2 by which p21 is suppressed based on the schematic summary of the LC–MS analysis. , P < 0.005; , P < 0.0001; N.S., not significant for indicated comparison.

Article Snippet: Antibodies specific for FOXO3 (2497, 12829), p21 (2947), CDK2 (2546), CDK-4 (12790), and cyclin D1 (2978) were purchased from Cell Signaling Technology.

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Liquid Chromatography with Mass Spectroscopy, Comparison

Figure 7. Functional consequences of FOXO3 O-GlcNAcylation in PDAC cells. In normal cells with well-controlled glucose and hexosamine metabolism, FOXO3 is normally active and is not O-GlcNAcylated at its S284 residue. However, in PDAC cells, which usually exhibit abnormal glucose and hexosamine metabolism, excessive O-GlcNAc production by the activated HBP leads to the O-GlcNAcylation of FOXO3 at S284 (marked as

Journal: Cancer Research

Article Title: O-GlcNAcylation of the Tumor Suppressor FOXO3 Triggers Aberrant Cancer Cell Growth

doi: 10.1158/0008-5472.can-17-3512

Figure Lengend Snippet: Figure 7. Functional consequences of FOXO3 O-GlcNAcylation in PDAC cells. In normal cells with well-controlled glucose and hexosamine metabolism, FOXO3 is normally active and is not O-GlcNAcylated at its S284 residue. However, in PDAC cells, which usually exhibit abnormal glucose and hexosamine metabolism, excessive O-GlcNAc production by the activated HBP leads to the O-GlcNAcylation of FOXO3 at S284 (marked as "G" in purple hexagonal box). This site- specific O-GlcNAcylation, a molecular switch, might abrogate the tumor suppressor activity of FOXO3, which likely turns on MDM2 activity, which is known to degrade both p53 and p21. The activated MDM2-mediated degradation of p53 and p21 consequently runs into uncontrolled cell-cycle state. Green arrows indicate those pathways newly identified from this work, whereas blue arrows represent those already known.

Article Snippet: Antibodies specific for FOXO3 (2497, 12829), p21 (2947), CDK2 (2546), CDK-4 (12790), and cyclin D1 (2978) were purchased from Cell Signaling Technology.

Techniques: Functional Assay, Residue, Activity Assay